Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia
Background and Objectives. Chronic myeloid leukemia (CML) is characterized by hyperproliferation of myeloid precursors, increased fibrosis, and neoangiogenesis in the bone marrow. Imatinib inhibits BCR-ABL tyrosine kinase produced due to reciprocal translocation t(9;22) in neoplastic CML cells. It r...
Saved in:
Main Authors: | Neetu Pandey, Geeta Yadav, Rashmi Kushwaha, Shailendra Prasad Verma, Uma Shankar Singh, Ashutosh Kumar, Prabhaker Mishra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/1835091 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
by: Monika Conchon, et al.
Published: (2009-01-01) -
Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
by: Aytan Shirinova
Published: (2024-03-01) -
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
by: Tolo Diebkilé Aïssata, et al.
Published: (2013-01-01) -
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01) -
Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia
by: Mireille Crampe, et al.
Published: (2017-01-01)